A new study published in The Lancet Psychiatry, titled “Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression: a placebo-controlled, double-blind, randomised trial in the UK“ presents the largest trial to date investigating the efficacy of pramipexole in treating treatment-resistant depression.
The study found that pramipexole augmentation of antidepressant treatment led to a reduction in symptoms compared to placebo at 12 weeks. While the treatment was associated with some adverse effects, the results suggest that pramipexole is a clinically effective option for reducing symptoms in patients with treatment-resistant depression.
Link to the publication.